Alexander N. Shoushtari

Author

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

A. N. Shoushtari, A. Shoushtari, A.N. Shoushtari, Alexander N Shoushtari, Alexander N. Shoushtari, Alexander Noor Shoushtari, Alexander Shoushtari, Alexander N. Shoushtari, Frances C Wright, Shoushtari A

381

Publications

22.4K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Columbia University Irving Medical Center Massachusetts General Hospital Vanderbilt University Medical Center

About

Alexander N. Shoushtari is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	48	12.6K
2	Health Sciences	7	7	3.6K
3	Cell Biology	4	4	384
4	Public Health	2	2	90
5	Epidemiology	1	1	76

Alexander N. Shoushtari

103

Publications

21.2K

Citations

H-Index

Page 1

	Year	Citations
Tumor mutational load predicts survival after immunotherapy across multiple cancer types Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Nature Genetics Cancer ImmunosurveillanceTumor HeterogeneityMedicineImmunologyPathology	2019	4.2K
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Ahmet Zehir, Ryma Benayed, Ronak Shah, Nature Medicine Metastatic CancerOncologySomatic VariantMutational LandscapeTumor Heterogeneity	2017	3.4K
OncoKB: A Precision Oncology Knowledge Base Debyani Chakravarty, Jianjiong Gao, Sarah Phillips, JCO Precision Oncology	2017	2.6K
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab Alexander M. Menzies, Douglas B. Johnson, Sangeetha Ramanujam, Annals of Oncology Autoimmune DisordersAutoimmune DiseaseAnti-pd-1 TherapyMelanomaImmunology	2016	811
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, New England Journal of Medicine	2021	806
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis Sandra P. D’Angelo, James Larkin, Jeffrey A. Sosman, Journal of Clinical Oncology Mucosal MelanomaPurpose Mucosal MelanomaMedicineMelanomaImmunology	2017	617
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients Bastien Nguyen, Christopher J. Fong, Anisha Luthra, Cell UrologyTumor HeterogeneityMedicineNext-generation SequencingPathology	2022	608
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors Cristina Valero, Mark Lee, Douglas R. Hoen, Nature Communications	2021	435
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma Megan H. Pollack, Helen Clare Dearden, K. Rapazzo, Annals of Oncology Cancer ImmunosurveillanceOncologyMelanomaImmunologyTumor Immunity	2017	381
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies Alain P. Algazi, Katy K. Tsai, Alexander N. Shoushtari, Cancer	2016	362

Page 1